---
title: "TB-500"
slug: "tb-500"
type: "compound"
category: "Recovery"
url: "https://peptidesciencethailand.com/compounds/tb-500"
description: "Synthetic fragment of Thymosin Beta-4 that supports tissue repair through actin-dependent cell migration. Evidence summary, protocols, and recovery context."
---
# TB-500

*Thymosin Beta-4, Cell Migration and Universal Tissue Repair*

**Category:** Recovery  
**Format:** Lyophilized Vial  
**Amount:** 5mg  
**Purity:** >99.4% (HPLC)

## Overview

TB-500 is a synthetic version of the naturally occurring 43-amino acid peptide Thymosin Beta-4 (Tβ4), one of the most abundant intracellular proteins in mammalian tissue. First isolated from the thymus gland, the organ responsible for T-cell maturation and immune system development, Thymosin Beta-4 was initially studied for its immunological properties before its remarkable tissue repair capabilities were discovered. TB-500 replicates the active region of the full Thymosin Beta-4 protein, focusing on the amino acid sequence responsible for its regenerative and anti-inflammatory effects.

The primary mechanism of TB-500 centers on its interaction with actin, the most abundant protein in eukaryotic cells and a fundamental component of the cellular cytoskeleton. TB-500 contains a central actin-binding domain, the sequence LKKTETQ (Leu-Lys-Lys-Thr-Glu-Thr-Gln), that enables it to sequester G-actin monomers, regulating actin polymerization and depolymerization dynamics. This regulation of the actin cytoskeleton directly controls cell migration, a process essential for wound healing and tissue repair. By promoting the formation of new actin filaments, TB-500 enables cells to move directionally toward injury sites, a process known as chemotaxis.

Beyond actin regulation, TB-500 promotes angiogenesis through mechanisms distinct from those of BPC-157. While BPC-157 acts primarily through VEGFR2, TB-500 promotes endothelial cell migration and tube formation through actin-dependent pathways, creating new capillary networks that supply healing tissue with oxygen and nutrients. Research published in the Annals of the New York Academy of Sciences demonstrated TB-500's ability to promote angiogenesis in both in vitro and in vivo models, with significant increases in endothelial cell migration and capillary sprouting.

TB-500 exhibits potent anti-inflammatory properties through downregulation of pro-inflammatory cytokines and chemokines. Research has shown it reduces levels of interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and nuclear factor kappa-B (NF-κB), key mediators of the inflammatory cascade. This anti-inflammatory action creates a more favorable healing environment while reducing pain and swelling associated with tissue injury.

The peptide also demonstrates unique properties in cardiac repair research. Studies in mouse models of myocardial infarction, published in the Proceedings of the National Academy of Sciences, showed that TB-500 treatment activated cardiac progenitor cells and promoted the formation of new cardiomyocytes from epicardial progenitor cells. This regenerative capacity in cardiac tissue has generated significant research interest, as the heart has historically been considered to have minimal regenerative potential.

TB-500's effects extend to hair follicle stem cell activation, wound healing acceleration, and reduction of fibrotic scar formation. Its ability to promote organized collagen deposition rather than disorganized scarring represents a significant advantage in musculoskeletal repair, potentially resulting in stronger, more functional healed tissue compared to untreated injuries.

specialist oversight for TB-500 protocols is important because its potent effects on cell migration and angiogenesis require assessment of individual health status. Its anti-inflammatory properties may interact with immune function, and its effects on cell proliferation pathways necessitate screening for individuals with certain pre-existing conditions.

## Mechanism of Action

### Step 1: G-Actin Sequestration

TB-500's LKKTETQ domain binds G-actin monomers, regulating the dynamic balance between G-actin and F-actin polymerization. This controls the actin cytoskeleton's structure and function within cells.

### Step 2: Enhanced Cell Migration

By promoting new actin filament formation, TB-500 enables directional cell migration (chemotaxis) toward injury sites. This is the fundamental process by which repair cells reach damaged tissue.

### Step 3: Angiogenesis via Endothelial Migration

TB-500 promotes endothelial cell migration and tube formation through actin-dependent pathways, creating new capillary networks that deliver oxygen and nutrients to healing tissue.

### Step 4: Anti-Inflammatory Cascade

TB-500 downregulates pro-inflammatory cytokines including IL-1β, TNF-α, and NF-κB signaling, reducing inflammation and creating a more favorable microenvironment for organized tissue repair.

### Step 5: Organized Tissue Remodeling

Rather than forming disorganized scar tissue, TB-500 promotes organized collagen deposition and stem cell activation, resulting in stronger, more functional healed tissue with reduced fibrosis.

## Researched Benefits

### Universal Tissue Repair

TB-500's mechanism of enhancing cell migration through actin regulation makes it effective across virtually all tissue types, muscle, tendon, ligament, bone, skin, and even cardiac tissue. This universality stems from actin being the most abundant protein in all eukaryotic cells.

### Potent Anti-Inflammatory Action

By downregulating key inflammatory mediators (IL-1β, TNF-α, NF-κB), TB-500 reduces pain and swelling at injury sites while creating an optimal healing microenvironment. This anti-inflammatory action is achieved without suppressing necessary immune surveillance functions.

### Reduced Scar Formation

TB-500 promotes organized collagen deposition rather than disorganized fibrotic scarring. This results in healed tissue that more closely resembles the original tissue structure, potentially improving functional outcomes in musculoskeletal injuries.

### Enhanced Angiogenesis

Through actin-dependent endothelial cell migration, TB-500 promotes new blood vessel formation at injury sites. This ensures adequate oxygen and nutrient delivery during the repair process, which is often a rate-limiting factor in healing.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 2-2.5mg administered subcutaneously twice weekly during loading phase, reducing to 2mg once weekly for maintenance |
| Route | Subcutaneous injection |
| Duration | 4-6 weeks loading, 2-4 weeks maintenance |
| Cycle Notes | Loading phase protocols typically administer higher doses twice weekly for 4-6 weeks, followed by reduced maintenance dosing. Some protocols use once-weekly dosing throughout for less acute conditions. |
| Reconstitution | Reconstitute with bacteriostatic water. Using 5mg with 2mL bacteriostatic water yields 2500mcg/mL. Gently swirl, do not shake. Store reconstituted solution at 2-8°C and use within 21 days. |

> **Specialist note:** TB-500 dosage should be determined by a specialist based on the specific injury type, severity, chronicity, and overall health profile. Loading and maintenance phase durations are adjusted based on clinical response and follow-up assessment.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 5mg per vial |
| Purity | >99.4% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | 43-amino acid sequence replicating the active region of Thymosin Beta-4, centered on the LKKTETQ actin-binding domain |
| Molecular Weight | 4963.50 g/mol |
| Storage | Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C. Protect from light. |
| Appearance | White to off-white lyophilized powder |

## Medical Guidance

TB-500's potent effects on cell migration and angiogenesis require specialist assessment before use. Its anti-inflammatory properties through NF-κB modulation may interact with immune function, making it important for individuals with autoimmune conditions or compromised immunity to undergo thorough evaluation. Its effects on cell proliferation pathways also necessitate screening for certain pre-existing conditions before initiating treatment.

## Frequently Asked Questions

### What is the difference between TB-500 and Thymosin Beta-4?

TB-500 is a synthetic peptide that replicates the active region of the naturally occurring 43-amino acid protein Thymosin Beta-4 (Tβ4). While the terms are often used interchangeably, technically TB-500 refers to the synthetic research compound while Thymosin Beta-4 is the endogenous protein. Both contain the critical LKKTETQ actin-binding domain responsible for the tissue repair and anti-inflammatory effects studied in research.

### What medical guidance applies to TB-500?

TB-500 is a compound studied in clinical research that should only be used under qualified medical supervision. A specialist consultation helps ensure proper assessment of the injury, determination of appropriate loading and maintenance dosing, and monitoring throughout the protocol. This is essential for safety because TB-500's effects on cell migration and angiogenesis require evaluation of complete health status.

### How does TB-500 differ from BPC-157 for recovery?

TB-500 and BPC-157 promote tissue repair through different mechanisms. TB-500 works primarily through actin regulation to enhance cell migration and reduce inflammation via cytokine modulation. BPC-157 works through VEGFR2 activation and nitric oxide production. Their complementary mechanisms are why many research protocols investigate them in combination. A specialist can determine which compound or combination best addresses specific condition.

### What types of injuries has TB-500 been studied for?

TB-500 has been studied in preclinical research for tendon injuries, muscle tears, ligament damage, skin wounds, cardiac injury (myocardial infarction), corneal injury, and neurological damage. Its universal mechanism of action, based on actin regulation present in all cell types, gives it a broader tissue application range than many other recovery peptides. Human clinical data is still emerging.

### What is the typical TB-500 protocol duration?

Research protocols typically involve a 4-6 week loading phase with twice-weekly injections at higher doses (2-2.5mg), followed by a maintenance phase of 2-4 weeks with reduced once-weekly dosing. Total protocol duration is usually 6-10 weeks. A your specialist will customize these timeframes based on the injury severity, healing progress, and individual response.

## Related Compounds

- /compounds/bpc-157
- /compounds/ghk-cu
- /compounds/cjc-1295-ipamorelin

## Comparisons

- /compare/bpc-157-vs-tb-500